Arushi Saini

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements.
  Cancer discovery 2025 DOI: 10.1158/2159-8290.cd-24-1726
  +Save
• Activating mutations in the MET kinase domain co-occur with other driver oncogenes and mediate resistance to targeted therapy in NSCLC.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 DOI: 10.1016/j.jtho.2025.03.045
  +Save
• Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
  Annals of Oncology 2024 DOI: 10.1016/j.annonc.2024.11.014
  +Save
• Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma
  JCO Precision Oncology 2024 DOI: 10.1200/po-24-00394
  +Save
• Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
  JTO Clinical and Research Reports 2024 DOI: 10.1016/j.jtocrr.2024.100675
  +Save
• Mitochondrial–nuclear heme trafficking in budding yeast is regulated by GTPases that control mitochondrial dynamics and ER contact sites
  Journal of Cell Science 2020 DOI: 10.1242/jcs.237917
  +Save
• Glyceraldehyde-3-phosphate dehydrogenase is a chaperone that allocates labile heme in cells
  Journal of Biological Chemistry 2018 DOI: 10.1074/jbc.ra118.004169
  +Save